PharmaCyte BiotechPMCB -1.09%32 OCF Yield % is -59.60 as of Jun. 26, 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, PharmaCyte Biotech ranks worse than 85.13% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PharmaCyte Biotech OCF Yield % Related Terms
PharmaCyte Biotech OCF Yield % Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PharmaCyte Biotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a OCF Yield % of -59.60 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #1208 out of 1419 companies in the Biotechnology industry, placing it in the top 85.1%.
Is PharmaCyte Biotech's OCF Yield % too high?
PharmaCyte Biotech's current OCF Yield % is -59.60. Based on the distribution chart, PharmaCyte Biotech ranks #1208 out of 1419 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's OCF Yield % compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #1208 out of 1419 companies for OCF Yield %. This places PharmaCyte Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current OCF Yield % is -59.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current OCF Yield % of -59.60. The current OCF Yield % is -59.60. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current OCF Yield % is -59.60 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
